Elacestrant in ER+, HER2- MBC with ESR1-mutated tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy Plus CDK4/6 Inhibitor and in Clinical Subgroups

Tupper HI, Mendelson DS, Doo FX, Carlos RC, Bialecki B, Prosper AE, Moghanaki D, Servais EL, Flores EJ, Cummings AL. Imaging Interoperability: #DitchtheDisk is a[...]

Alkassis S, Suresh Y, Lipsyc-Sharf M, Zhang S, Gianni C, Medford A, Bardia A, Ashouri S, Kapoor N. Circulating tumor DNA detection of local recurrence[...]

Green-Lott AY, Wadhwa A, Bailey AV, Kwan L, Haroldsen CL, Shelton JB, Lewis MS, Beenhouwer DO, Chamie K, Rose BS, Maxwell KN, Nickols NG, Yamoah[...]